Assura PLC (LON:AGR)‘s stock had its “hold” rating reissued by equities research analysts at Liberum Capital in a research report issued on Monday. They presently have a GBX 60 ($0.75) target price on the real estate investment trust’s stock. Liberum Capital’s target price would indicate a potential upside of 0.84% from the company’s current price.

Separately, Peel Hunt restated a “hold” rating and issued a GBX 55 ($0.69) target price on shares of Assura PLC in a research report on Tuesday, November 22nd.

Assura PLC (LON:AGR) opened at 59.4435 on Monday. Assura PLC has a 12-month low of GBX 48.08 and a 12-month high of GBX 61.00. The company’s 50-day moving average price is GBX 58.93 and its 200-day moving average price is GBX 57.68. The stock’s market cap is GBX 972.76 million.

TRADEMARK VIOLATION WARNING: “Assura PLC’s (AGR) “Hold” Rating Reaffirmed at Liberum Capital” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The correct version of this article can be accessed at

About Assura PLC

Assura plc is a United Kingdom-based healthcare real estate investment trust (REIT). The Company is a primary care property investor and developer. The Company develops, invests and manages a portfolio of primary care medical centers across the United Kingdom. The Company’s property portfolio includes Alwoodley Medical Centre, Leeds; Fleetwood Health and Wellbeing Centre, Fleetwood; Frome Medical Practice, Frome; Claremont Medical Centre, Surbiton; Elbury Moor Medical Centre; Grey Gable Surgery; Trellech Surgery; Bewdley Medical Centre; Malmesbury Primary Care Centre, Malmesbury, and Urmston Group Practice, Urmston.

Receive News & Stock Ratings for Assura PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assura PLC and related stocks with our FREE daily email newsletter.